Today, the presidents of Senegal, Rwanda and Ghana, as well as WHO general director Tedros Ghebreyesus, travelled to Marburg for the latest BioNTech product launch. There they all posed for photos with the vaccine tycoon and BioNTech CEO Uğur Şahin, while he introduced them to the BioNTainer, a semi-mobile vaccine factory cobbled together out of six shipping containers. The message: Africa will be a vaccine importer no longer. Soon, Africans will get their own factories, just like we have here. When it’s finally up and running, each BioNTainer will be capable of churning out up to 50 million doses a year!
Well, kind of. Actually, probably not. Reuters reports that the BioNTainers “will require a hall of about 800 square metres,” as well as (of course) local infrastructure and local quality control testing laboratories – all of which the host countries will have to supply. In other words, these aren’t mobile factories at all; they’re just containers full of laboratory equipment with cool green lighting and an emergency eyewash station.
Also too, these wunderlabs will have to be staffed BioNTech personnel, until the company can train “local partners to take over the complex vaccine making procedure,” and production won’t begin until the middle of 2023.
It does not take a genius to figure out what is going on here. On the one hand, something like less than 15% of Africa is fully vaccinated, which is a bad look for globalist politicians who want to blame the continued existence of SARS-2 on tiny unvaccinated first-world minorities. On the other hand, the EU and Germany continue to defend BioNTech’s vaccine patents before the World Trade Organisation, betraying to all and sundry that there are indeed more important things than lipid nanoparticles in every bloodstream.
Even the establishment press smells a rat here. The SZ:
The BioNTech plan is too slow, complains vaccine expert Lara Dovifat … In a study, Médecins Sans Frontières identified 120 pharmaceutical companies in the global south that would be able to start producing mRNA vaccines within months, if Biontech agreed to a technology transfer.
Yes, but then Özlem Türeci wouldn’t make any money, so that’s no good. The SZ again:
The timing of the [BioNTainer roll-out] in Marburg might be a coincidence, but just last Friday, the WHO Vaccine Technology Transfer Hub consortium presented their plans for vaccine production in the laboratories of Afrigen in Cape Town. Their vaccine is based on publicly available information from the Moderna vaccine. Afrigen has already produced it; clinical trials are set to begin at the end of the year. They say that production is perhaps three years away; ten million doses a year are planned.
So the BioNTainer is vaporware, designed to put a happy face on the fact that the German pharmaceutical is in no hurry to start making vaccines in Africa, given that their closest competitor on that continent is years away from going into production.